PMC4749787_01
Pet CT showing accumulation of 18-FDG in the right parotid gland.
CRIONM2016-3965283.001.jpg
PMC4749787_01_CRIONM2016-3965283.001.jpg
fig1
Staging FDG-PET CT scan was obtained showing accumulation of 18-FDG in the right parotid and ruled out other distant or locoregional metastases (Figure 1).
Parotid: H&E x40: neoplastic ducts (right upper part of the image) invading the parotid parenchyma (left lower part of the image).
CRIONM2016-3965283.002.jpg
PMC4749787_01_CRIONM2016-3965283.002.jpg
fig2
The anatomic pathology report confirmed the secondary nature of the tumor (of breast origin) invading the parotid parenchyma with perineural and perivascular invasion (Figure 2).
Parotid: immunostain with anti-estrogen receptors antibody x40: the nuclei of the malignant cell are highlighted in brown. Parotid ducts are seen in the lower part of the image.
CRIONM2016-3965283.003.jpg
PMC4749787_01_CRIONM2016-3965283.003.jpg
fig3
Although immunocytochemistry was not done on the FNA sample and was not needed for diagnosis, immunostaining with anti-estrogen receptor (ER) antibodies was performed on the final surgical pathology specimen and further supported the diagnosis as the tumoral cells were ER positive (Figure 3).
GATA3 nuclear expression in neoplastic cells (GATA3 immunostaining x200) confirming the breast origin of the parotid tumor.
CRIONM2016-3965283.004.jpg
PMC4749787_01_CRIONM2016-3965283.004.jpg
fig4
GATA3 immunostaining, a specific marker for breast cancer, was also done confirming the breast origin of the tumor (Figure 4).